Banco Santander S.A. Makes New Investment in IQVIA Holdings Inc. (NYSE:IQV)

Key Points

• Banco Santander S.A. acquired approximately 119,292 shares of IQVIA Holdings Inc., valued at around $21 million, representing about 0.07% ownership by the end of the last quarter.
• Recent analyst ratings for IQVIA have been positive, with target prices raised by firms like Mizuho and UBS Group, now ranging from $196 to $225, indicating a strong outlook for the company.
• The latest earnings report showed IQVIA beating analyst expectations with $2.81 EPS and $4.02 billion in revenue, reflecting a year-over-year revenue growth of 5.3%.

Banco Santander S.A. bought a new position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 119,292 shares of the medical research company's stock, valued at approximately $21,031,000. Banco Santander S.A. owned about 0.07% of IQVIA as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Continuum Advisory LLC raised its position in shares of IQVIA by 3.7% in the 4th quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock worth $354,000 after buying an additional 64 shares during the period. Ballentine Partners LLC increased its holdings in IQVIA by 4.9% in the 1st quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company's stock valued at $260,000 after purchasing an additional 69 shares in the last quarter. ST Germain D J Co. Inc. raised its position in IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after purchasing an additional 76 shares during the period. Nemes Rush Group LLC lifted its stake in shares of IQVIA by 15.0% during the first quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company's stock worth $109,000 after purchasing an additional 81 shares in the last quarter. Finally, Quadrant Capital Group LLC grew its stake in shares of IQVIA by 10.7% in the fourth quarter. Quadrant Capital Group LLC now owns 928 shares of the medical research company's stock valued at $182,000 after buying an additional 90 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Price Performance

Shares of NYSE IQV traded up $0.52 during trading on Monday, hitting $182.97. The company had a trading volume of 1,100,457 shares, compared to its average volume of 2,403,455. The company has a market cap of $31.10 billion, a P/E ratio of 26.48, a PEG ratio of 2.00 and a beta of 1.30. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. The business's 50-day moving average is $162.11 and its 200 day moving average is $169.70. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. During the same period in the prior year, the firm earned $2.64 earnings per share. The business's quarterly revenue was up 5.3% on a year-over-year basis. Equities research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IQV has been the topic of several recent research reports. JPMorgan Chase & Co. reduced their price target on IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research report on Monday, May 19th. Barclays raised their price target on shares of IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a report on Wednesday, July 23rd. Truist Financial upped their price objective on shares of IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Mizuho lifted their target price on IQVIA from $190.00 to $225.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Finally, Robert W. Baird upped their price target on IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a research report on Wednesday, July 23rd. Seven equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $228.62.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the transaction, the insider owned 27,178 shares in the company, valued at $5,165,178.90. This represents a 17.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Keriann Cherofsky sold 549 shares of the stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares of the company's stock, valued at approximately $557,352.30. The trade was a 15.87% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.